Get started
Author

Michael Watt

Observed name: M Watt
Observed institution: AstraZeneca (United Kingdom)
ORCID: 0009-0005-4313-5735
Observed ORCID: 0009-0005-4313-5735
OpenAlex ID: A5057618841
Benralizumab in severe eosinophilic asthma by previous biologic use and key clinical subgroups: real-world XALOC-1 programme
2024 · David J. Jackson, Girolamo Pelaia, et al. · European Respiratory Journal · 60
Improving asthma care through implementation of the SENTINEL programme: findings from the pilot site
2023 · Michael G. Crooks, Lucia Crowther, et al. · ERJ Open Research · 23
PDF
Overcoming Barriers to Remission in Severe Eosinophilic Asthma: Two‐Year Real‐World Data With Benralizumab
2024 · David J. Jackson, Hassan Burhan, et al. · Clinical & Experimental Allergy · 22
PDF
XALOC-1
2025 · Girolamo Pelaia, David J. Jackson, et al. · CHEST Journal · 16
PDF
P10 Breathless systems: COPD pressures in hospitals across England
2025 · REK Russell, M Bafadhel, et al. · Thorax · 1
Benralizumab in severe eosinophilic asthma by biologic use and key clinical subgroups: real-world XALOC-1 programme: a plain language summary of publication
2025 · David J. Jackson, Girolamo Pelaia, et al. · Immunotherapy · 1
PDF
Asthma outcomes in patients (pts) with severe eosinophilic asthma (SEA), with and without comorbid chronic rhinosinusitis with nasal polyps (NP), treated with benralizumab in the real-world XALOC-1 study
2023 · Girolamo Pelaia, Alicia Padilla-Galo, et al. · European Respiratory Journal · 1
Late Breaking Abstract - Patients with severe eosinophilic asthma achieved remission over 2 years with benralizumab: Integrated analysis of the >1000-patient, multinational, real-world XALOC-1 study
2023 · Girolamo Pelaia, David J. Jackson, et al. · European Respiratory Journal · 1
P11 Characteristics and long-term real-world outcomes of severe asthma patients treated with benralizumab in the United Kingdom; the BPAP study
2022 · DJ Jackson, H Burhan, et al. · Thorax · 1
Real-World Effectiveness of Budesonide/Glycopyrronium/Formoterol (BGF) Fixed-Dose Combination in Patients with COPD (RECORD Study): A Prospective Observational Study
2026 · Henrik Watz, Michael Watt, et al. · International Journal of COPD
PDF
Barriers and facilitators to practitioner prescribing and patient adoption of anti-inflammatory maintenance and reliever therapy (MART) for adult asthma: a qualitative study
2026 · Judith Dyson, Helena Cummings, et al. · BMC Family Practice
Estimation of Health Utility Values for Eosinophilic Granulomatosis With Polyangiitis
2025 · Bhovina Buguth, Jacqui Bernarde, et al. · PharmacoEconomics - Open
PDF
P14 Under pressure: patient characteristics associated with primary care respiratory treatment reviews before respiratory winter pressures in the UK
2025 · PE Pfeffer, MJ Hale, et al. · Thorax
Real-world outcomes of Budesonide/Glycopyrronium/Formoterol therapy in COPD after 12 months; the RECORD study
2025 · Henrik Watz, Marija Halbach, et al. · European Respiratory Journal
PCR157 Estimated Impact of Pre-Exposure Prophylaxis for COVID-19 on Quality of Life and Physical Distancing Among Immunocompromised Individuals and Caregivers
2025 · Rebekah Hall, Elina Matter, et al. · Value in Health
Real-world outcomes of Budesonide/Glyccopyronium/Formoterol therapy in COPD after 6 months; interim results of the RECORD study
2025 · H Watz, M Halbach, et al. · Pneumologie
P20 Effectiveness of benralizumab in patients with severe asthma previously treated with mepolizumab in the United Kingdom; a BPAP study post-hoc analysis
2024 · DJ Jackson, H Burhan, et al. · Thorax
Characteristics of patients with COPD treated with Budesonide/Glycopyrronium/Formoterol in the real world; The RECORD Study
2024 · Henrik Watz, Marija Halbach, et al. · European Respiratory Journal
Real-world outcomes of Budesonide/Glycopyrronium/Formoterol therapy in COPD after 3 months; Interim analysis of the RECORD study
2024 · Henrik Watz, Marija Halbach, et al. · European Respiratory Journal
Estimating the Health-Related Quality of Life Benefit of Prophylactic Treatment for COVID-19 in Immunocompromised People: A Multimethod Valuation Study
2024 · Katy Gallop, Rebekah Hall, et al. · Journal of health economics and outcomes research
Baseline characteristics of patients with COPD treated with Budesonide/Glycopyrronium/Formoterol in the real world; the RECORD study
2024 · H Watz, M Halbach, et al. · Pneumologie
P131 Patients with severe eosinophilic asthma achieved remission over 2 years with benralizumab: integrated analysis of the >1000-patient, multinational, real-world XALOC-1 study
2023 · G Pelaia, DJ Jackson, et al. · Thorax
PDF
P130 Clinical effectiveness over 2 years of benralizumab treatment in patients with severe eosinophilic asthma and concomitant nasal polyposis; analysis from the BPAP study
2023 · DJ Jackson, H Burhan, et al. · Thorax
PDF
M25 Reductions in healthcare resource utilisation (HCRU) over 2 years of benralizumab treatment in patients with severe eosinophilic asthma; analysis from the BPAP study
2023 · DJ Jackson, H Burhan, et al. · Thorax
PDF
Works count: 24
Citation count: 126
H-index: 4
I10-index: 4
Year
Topic
Type